GENEVA / Mar 20, 2023 / Business Wire / Alcon (SIX/NYSE: ALC), the global leader in eye care, will host its 2023 Capital Markets Day on March 30, 2023 beginning at 8:00 a.m. CT.
A live webcast of the event will be available at https://investor.alcon.com/news-and-events/events-and-presentations/default.aspx.
About Alcon
Alcon helps people see brilliantly. As the global leader in eye care with a heritage spanning over 75 years, we offer the broadest portfolio of products to enhance sight and improve people’s lives. Our Surgical and Vision Care products touch the lives of more than 260 million people in over 140 countries each year living with conditions like cataracts, glaucoma, retinal diseases and refractive errors. Our more than 25,000 associates are enhancing the quality of life through innovative products, partnerships with Eye Care Professionals and programs that advance access to quality eye care. Learn more at www.alcon.com.
Connect with us on
Facebook
LinkedIn
| Last Trade: | US$84.76 |
| Daily Change: | 0.58 0.69 |
| Daily Volume: | 910,846 |
| Market Cap: | US$41.920B |
November 12, 2024 November 07, 2024 August 20, 2024 June 24, 2024 | |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
